USE OF PRODRUGS OF FUMARATES IN TREATING HEART FAILURE DISEASES

    公开(公告)号:US20190167638A1

    公开(公告)日:2019-06-06

    申请号:US16266548

    申请日:2019-02-04

    IPC分类号: A61K31/4015 A61K45/06

    摘要: Methods and pharmaceutical compositions comprising one or more prodrugs (e.g., aminoalkyl prodrugs) of monomethyl fumarate (MMF) thereof are provided herein for the treatment of a heart failure disease, including heart failure with preserved ejection fraction. The compounds of the present disclosure are configured to be converted in vivo, upon oral administration, to monomethyl fumarate. Upon conversion, the active moiety (i.e., monomethyl fumarate) of various embodiments is effective in treating subjects suffering from a heart failure disease, including heart failure with preserved ejection fraction.

    METHODS OF TREATING HEART FAILURE USING FATTY ACID FUMARATE DERIVATIVES

    公开(公告)号:US20170258751A1

    公开(公告)日:2017-09-14

    申请号:US15457908

    申请日:2017-03-13

    IPC分类号: A61K31/232

    CPC分类号: A61K31/232

    摘要: Pharmaceutical compositions comprising Fatty Acid Fumarate Derivatives, and methods of using Fatty Acid Fumarate Derivatives and pharmaceutical compositions thereof for treating heart failure diseases, including heart failure with preserved ejection fraction (HFPEF), comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative alone or in combination with statins (HMG-CoA reductase inhibitors) are disclosed.

    UTILIZATION OF DIALKYL FUMARATES IN TREATMENT OF HEART FAILURE
    8.
    发明申请
    UTILIZATION OF DIALKYL FUMARATES IN TREATMENT OF HEART FAILURE 审中-公开
    DIALKYL FUMARATES在心力衰竭治疗中的应用

    公开(公告)号:US20170056356A1

    公开(公告)日:2017-03-02

    申请号:US15249744

    申请日:2016-08-29

    摘要: Pharmaceutical preparations and methods for treating or preventing a heart failure disease, including heart failure with preserved ejection fraction (HFPEF), with one or more dialkyl fumarates alone or in combination with one or more second agents are provided herein. In some embodiments, the pharmaceutical preparations are in the form of micro-tablets or pellets.

    摘要翻译: 本文提供了用于治疗或预防心力衰竭疾病的药物制剂和方法,包括具有保留的射血分数(HFPEF)的心力衰竭,单独使用一种或多种富马酸二烷基酯或与一种或多种第二药剂组合。 在一些实施方案中,药物制剂是微片剂或丸剂的形式。

    COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
    9.
    发明申请
    COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEXUAL DYSFUNCTION 审中-公开
    用于治疗性功能障碍的组合物和方法

    公开(公告)号:US20160354444A1

    公开(公告)日:2016-12-08

    申请号:US15173398

    申请日:2016-06-03

    摘要: Described herein are pharmaceutical compositions for the treatment of sexual dysfunction in an individual. In some embodiments, the pharmaceutical composition includes a prolactin variant having a glycine residue at position 129 substituted with an amino acid other than glycine. In one embodiment, the amino acid is arginine. In one embodiment, the prolactin variant further comprises an N-terminal deletion. In one embodiment, the prolactin variant is conjugated to a H(OCH2CH2)nOH molecule (e.g., n equals any number from 1 to 6). In some embodiments, the pharmaceutical composition is delivered to the individual by a microneedle patch or an inhalable formulation.

    摘要翻译: 本文描述的是用于治疗个体性功能障碍的药物组合物。 在一些实施方案中,药物组合物包含催乳素变体,其在129位被甘氨酸除非甘氨酸以外的氨基酸取代。 在一个实施方案中,氨基酸是精氨酸。 在一个实施方案中,催乳素变体还包含N-末端缺失。 在一个实施方案中,催乳素变体与H(OCH 2 CH 2)n OH分子缀合(例如,n等于1至6的任何数)。 在一些实施方案中,药物组合物通过微针补片或可吸入制剂递送至个体。

    Use of prodrugs of fumarates in treating heart failure diseases

    公开(公告)号:US10213411B2

    公开(公告)日:2019-02-26

    申请号:US15249820

    申请日:2016-08-29

    IPC分类号: A61K31/4015 A61K45/06

    摘要: Methods and pharmaceutical compositions comprising one or more prodrugs (e.g., aminoalkyl prodrugs) of monomethyl fumarate (MMF) thereof are provided herein for the treatment of a heart failure disease, including heart failure with preserved ejection fraction. The compounds of the present disclosure are configured to be converted in vivo, upon oral administration, to monomethyl fumarate. Upon conversion, the active moiety (i.e., monomethyl fumarate) of various embodiments is effective in treating subjects suffering from a heart failure disease, including heart failure with preserved ejection fraction.